证券代码：002178 证券简称：延华智能 公告编号：2024-023 上海延华智能科技（集团）股份有限公司 关于对控股子公司上海东方延华节能技术服务股份 有限公司的续贷继续提供担保的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 为满足上海延华智能科技（集团）股份有限公司（以下简称"延 华智能"或"公司"）控股子公司上海东方延华节能技术服务股份有 限公司（以下简称"东方延华"）的日常经营需要，确保其资金流畅 通，东方延华向南京银行股份有限公司上海分行（以下简称"贷款方"） 申请 1,000 万元最高债权额（以下简称"原贷款"），公司提供连带责 任保证担保。现原贷款已到期并还清，东方延华向贷款方申请续贷 1,000 万元贷款，公司继续提供连带责任保证担保。 二、担保审议情况 公司于 2023 年 4 月 18 日、2023 年 5 月 12 日分别召开公司第五 届董事会第三十五次会议、第五届监事会第十九次会议、2022 年年度 股东大会，审议通过《关于公司预计为控股子公司提供担保额度的议 案》，同意公司自 2022 年年度股东大会通过之 ...

Revenue and Profitability - Revenue for Q1 2024 was CNY 149,729,406.60, an increase of 7.13% compared to CNY 139,770,245.29 in the same period last year[5] - Net profit attributable to shareholders was a loss of CNY 4,993,149.63, a decrease of 361.81% from a profit of CNY 1,907,139.81 in the previous year[5] - Total operating revenue for Q1 2024 was CNY 149,735,780.12, an increase of 7.0% compared to CNY 139,773,610.08 in Q1 2023[24] - Net loss for Q1 2024 was CNY 5,745,229.61, compared to a net profit of CNY 1,808,916.67 in Q1 2023[25] - The total comprehensive income for the first quarter was -4,993,149.63 CNY, compared to 1,907,139.81 CNY in the previous period, indicating a significant decline[26] - Basic and diluted earnings per share were both -0.007 CNY, compared to 0.0027 CNY in the previous period[26] Cash Flow and Financial Activities - The net cash flow from operating activities improved by 44.20%, reaching a negative CNY 54,081,564.55 compared to negative CNY 96,911,990.07 in the previous year[5] - Cash inflow from operating activities totaled 177,547,182.22 CNY, down from 195,604,892.02 CNY year-over-year[27] - Cash outflow from operating activities was 231,628,746.77 CNY, compared to 292,516,882.09 CNY in the previous period[27] - The net cash flow from investing activities was -36,421,444.91 CNY, worsening from -13,522,905.82 CNY in the previous period[28] - Cash inflow from financing activities was 36,880,602.14 CNY, down from 63,828,158.28 CNY in the previous period[28] - The net cash flow from financing activities was -8,162,598.03 CNY, compared to 5,866,747.45 CNY in the previous period[28] - The ending balance of cash and cash equivalents was 243,891,996.34 CNY, slightly down from 245,923,909.35 CNY in the previous period[28] Assets and Liabilities - Total assets decreased by 4.25% to CNY 1,538,128,898.04 from CNY 1,606,426,197.00 at the end of the previous year[5] - Current liabilities decreased to CNY 822,253,366.55 from CNY 904,966,708.28 in the previous year[22] - Non-current liabilities increased to CNY 87,648,995.68 from CNY 67,487,723.30 year-over-year[22] - The company's total assets decreased to CNY 1,538,128,898.04 from CNY 1,606,426,197.00 year-over-year[22] - The total equity attributable to shareholders decreased to CNY 445,180,391.21 from CNY 450,173,540.84 year-over-year[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 88,028[11] - The top shareholder, Huarong (Tianjin Free Trade Zone) Investment Co., Ltd., holds 17.41% of the shares, totaling 123,983,721 shares[11] Operational Metrics - The weighted average return on equity was -1.12%, down from 0.45% in the same period last year, indicating a decline in profitability[5] - Research and development expenses for Q1 2024 were CNY 9,886,997.77, slightly up from CNY 9,532,535.53 in Q1 2023[25] - The company reported an investment income of CNY 359,859.45, a significant improvement from a loss of CNY 87,477.89 in the previous year[25] Inventory and Receivables - Accounts receivable increased by 117.27% compared to the beginning of the period, primarily due to an increase in unconfirmed receivable acceptance bills[7] - Accounts receivable increased from CNY 298.05 million to CNY 303.76 million, reflecting a growth of about 1.2%[20] - Inventory rose from CNY 59.91 million to CNY 73.43 million, marking an increase of approximately 22.6%[20] - The company reported a significant increase in contract assets, which decreased from CNY 244.37 million to CNY 238.57 million, a decline of about 2.4%[20] - The company's prepayments increased from CNY 6.82 million to CNY 8.48 million, reflecting a growth of approximately 24.4%[20] Regulatory and Compliance Issues - The company faced regulatory scrutiny, receiving a warning and fine from the China Securities Regulatory Commission on January 6, 2024[13] - The company experienced abnormal stock trading fluctuations, with a cumulative price deviation exceeding 20% over two consecutive trading days[16] Other Financial Changes - Loans and advances decreased by 100% as the subsidiary returned previously issued loans[8] - Construction in progress decreased by 49.69% as projects were completed and transferred to fixed assets[8] - The company completed the registration of changes in equity for eight companies, which hold real estate in Shanghai, as part of debt recovery efforts[15] - The company did not report any net profit from the merged entity prior to the merger, with previous net profit also reported as 0.00 CNY[26]

Financial Performance - The company's operating revenue for 2023 was ¥675,512,460.15, representing a 7.91% increase compared to ¥625,975,712.82 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥22,506,370.84, a significant turnaround from a net loss of ¥146,307,221.40 in 2022, marking a 115.38% improvement[20]. - The net profit after deducting non-recurring gains and losses was -¥20,592,178.60 in 2023, compared to ¥167,040,636.00 in 2022, indicating an 87.67% decline[20]. - The basic earnings per share for 2023 was ¥0.03, a recovery from -¥0.21 in 2022, reflecting a 114.29% increase[20]. - The total assets at the end of 2023 were ¥1,606,426,197.00, down 1.51% from ¥1,630,810,820.98 at the end of 2022[20]. - The net assets attributable to shareholders increased by 6.72% to ¥450,173,540.84 in 2023 from ¥421,850,460.10 in 2022[20]. - The cash flow from operating activities for 2023 was ¥28,238,950.09, a decrease of 23.35% from ¥36,840,920.89 in 2022[20]. - The company reported a weighted average return on equity of 5.16% in 2023, recovering from -29.46% in 2022[20]. - The revenue from green smart city services, excluding real estate leasing, was ¥672,070,552.76 in 2023, compared to ¥622,741,050.30 in 2022[21]. - The company achieved a total operating revenue of 67,551.25 million yuan in 2023, representing a year-on-year increase of 7.91%[74]. - The net profit attributable to shareholders was 2,250.64 million yuan, marking a turnaround from loss to profit compared to the previous year[74]. - The revenue from the smart healthcare and big health segment was 222,716.07 million yuan, accounting for 32.97% of total revenue, with a year-on-year growth of 34.81%[77]. - The green dual-carbon and digital energy segment generated 71,141.18 million yuan, reflecting a 41.06% increase year-on-year[77]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in 2023, representing a 20% year-over-year growth[151]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming for 1.875 billion in total revenue[151]. Strategic Focus and Development - The company operates in various sectors including energy-saving technology, medical information, and intelligent management systems[17]. - The company emphasizes the importance of risk awareness for investors regarding future plans and forecasts[4]. - The healthcare sector is expected to see rapid growth due to increasing digitalization demands and government support, aligning with the company's strategic focus[31]. - The company is positioned to benefit from the ongoing digital transformation in the construction industry, emphasizing the integration of digital technologies[34]. - The company aims to enhance service quality in software, cloud platforms, and information services to support high-quality development in the construction sector[36]. - The company is actively involved in the development of smart hospitals and healthcare information systems, which are projected to grow significantly in the coming years[31]. - The company focuses on a "1+3+5" development strategy in the healthcare sector, which includes one foundation (hospital information system) and three platforms (smart hospital, smart regional, and smart health care) supported by five technologies (cloud computing, big data, IoT, AI, and robotics)[43]. - The company aims to enhance hospital management and service capabilities through a comprehensive smart hospital information system that integrates electronic medical records, smart management, and online patient services[46]. - The company is committed to providing integrated health care services that combine medical, pharmaceutical, and insurance elements to meet diverse rehabilitation needs[47]. - The company is focused on developing a new generation of healthcare solutions, including mobile nursing systems and public health service systems, to support the digital health management ecosystem[52]. - The company is exploring potential acquisitions to strengthen its position in the smart technology sector, with a budget of 300 million allocated for this purpose[151]. Legal and Compliance Issues - The company is currently facing legal risks related to administrative penalties for information disclosure violations, with ongoing civil lawsuits from investors[132]. - The company has initiated legal action against Beijing Zhonghui Qianding Investment Management Co., Ltd. for failing to meet the 2021 performance commitment, seeking to enforce the buyback of its shares in Beijing Taihe Kang Medical Biotechnology Co., Ltd.[186]. - The company is actively involved in legal proceedings that may impact its financial position and cash flow[197]. - The company is managing multiple legal disputes that could affect its operational strategy and market expansion plans[197]. - The company is pursuing claims for engineering fees of 6.5749 million yuan and has faced counterclaims of 2.7626 million yuan[197]. - The company is involved in a legal case with Tianjin Matrix Communication Engineering Co., Ltd., seeking 131.6 million yuan in payment[198]. - The company has received a court ruling requiring payment of 497.43 million yuan in a construction contract dispute, with interest included[198]. - The company is actively pursuing multiple legal avenues to recover outstanding payments and enforce judgments[199]. Research and Development - The company has made significant investments in R&D, with 19 new software copyrights and 4 invention patents obtained in the smart healthcare sector[76]. - The company is in the research phase of developing a structured and intelligent medical record document engine to meet market demands[94]. - The integration platform V3.0 has been completed, which is expected to increase product sales and strengthen the company's market competitiveness[94]. - The company is focusing on improving the operational capabilities of grassroots medical services and enhancing service quality[94]. - The company is investing in R&D, with a budget increase of 15% for new technology development[156]. Market Expansion and Partnerships - The company plans to expand its market presence in Southeast Asia, targeting a 15% market share by 2025[147]. - A strategic acquisition of a local tech firm is in progress, expected to enhance the company's capabilities in smart technology solutions[147]. - The company is actively pursuing new partnerships and investments to bolster its market position and drive future growth[108]. - The establishment of new entities is part of a broader strategy to diversify and expand the company's portfolio[108]. - The company has completed the registration of eight subsidiaries, holding 100% equity in them, which collectively own eight properties in Minhang District, Shanghai, valued at approximately RMB 108.91 million as of November 30, 2023[111]. Governance and Management - The company has a governance structure that complies with relevant laws and regulations, with a board of 7 directors, including 3 independent directors[136]. - The company has established a complete independent business operation, with no reliance on controlling shareholders or related parties[140]. - The company has implemented a comprehensive employee management system, ensuring independence from controlling shareholders[141]. - The company has established four specialized committees under the board, including audit and strategy committees, to enhance governance[136]. - The company has a transparent information disclosure process, aiming for fairness and timeliness in sharing information with shareholders[137]. Operational Efficiency and Cost Management - The company is focusing on enhancing project management and selecting quality projects to improve overall profitability[122]. - The company has implemented cost-cutting measures, aiming to reduce operational expenses by 8% in the next fiscal year[145]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs through process optimization[151]. - The company has implemented organizational adjustments to improve operational efficiency and profitability[159]. Employee and Talent Management - The company is focused on talent development, implementing strategies to enhance workforce quality and structure to meet business expansion needs[70]. - The company recognizes talent retention as crucial for growth, implementing measures to attract and stabilize high-quality talent[130]. - The total number of employees at the end of the reporting period is 860, with 126 in the parent company and 734 in major subsidiaries[169]. - The technical staff constitutes the largest group with 545 employees, representing approximately 63.5% of the total workforce[169]. Environmental and Social Responsibility - The company is committed to achieving carbon peak and carbon neutrality goals, promoting low-carbon development and green transformation[91]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[180]. - The company is not classified as a key pollutant discharge unit and adheres to relevant environmental laws and regulations[180].

上海延华智能科技（集团）股份有限公司 关于举办 2023 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海延华智能科技（集团）股份有限公司（以下简称"公司"） 将于 2024 年 5 月 8 日（星期三）15:00－17:00 在全景网举办 2023 年 度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投 资者可登陆全景网"投资者关系互动平台"(https://ir.p5w.net) 参 与本次年度业绩说明会。 证券代码：002178 证券简称：延华智能 公告编号：2024-022 欢迎广大投资者积极参与本次业绩说明会。 （问题征集专题页面二维码） 特此公告。 上海延华智能科技(集团)股份有限公司 董事会 2024 年 4 月 30 日 出席本次年度业绩说明会的人员有：上市公司董事长龚保国先生、 总裁兼财务总监黄慧玲女士、执行总裁施学群先生、董事会秘书王垒 宏先生和独立董事洪芳芳女士。 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建议。 投资者可于 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-006 上海延华智能科技（集团）股份有限公司 关于公司部分债权回收进展 暨完成股权工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、背景情况概述 同时，公司已根据与中汇乾鼎及案外人暨八家公司原持有人上海 政殿科技有限公司（以下简称"上海政殿"）签订的协议书，承担上 海政殿主张的前期受让八家公司股权所产生的税费、佣金及八家公司 的运营费用等共计 3,500 万元；结合八家公司的评估价值等，公司收 到的净值合计约为 7,390.99 万元。 三、本次部分债权的回收对公司影响 本次八家公司股权转让已全部完成，根据八家公司最终完成变更 登记、移交等相关手续的不同时点，扣除相关成本、税、费的影响后， 将对上市公司的净利润产生正向影响，具体情况已在 2023 年 12 月 27 日的《关于公司相关诉讼进展情况暨部分债权回收的公告》（公告编 号：2023-049）中披露，截止本公告日并未发生重大变化，最终影响 数据以年审会计师的意见为准。 四、其他说明 1、公司将持续密切关注和高度重视与中 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-007 上海延华智能科技（集团）股份有限公司 关于独立董事任期届满离任的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 上海延华智能科技（集团）股份有限公司（以下简称"公司"） 收到公司独立董事洪芳芳女士递交的书面辞职报告，根据中国证监会 《上市公司独立董事管理办法》的规定，独立董事连续任职时间不得 超过六年，洪芳芳女士因连续任职时间满六年，申请辞去公司独立董 事职务。辞职后，洪芳芳女士不再担任公司独立董事及董事会专门委 员会委员职务，亦不担任公司及子公司的任何职务。截至本公告披露 日，洪芳芳女士未持有公司股份，不存在其应当履行而未履行的承诺 事项。 洪芳芳女士的离任将导致公司董事会专门委员会中独立董事所 占比例不符合《上市公司独立董事管理办法》等法律法规的规定，根 据规定，洪芳芳女士的辞职报告将在公司股东大会选举出新任独立董 事之日生效。在此期间，洪芳芳女士仍将按照有关法律、法规和《公 司章程》的规定，继续履行独立董事及公司董事会专门委员会委员的 职责。公司于日前收到深圳证券交易所下发的关 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-005 上海延华智能科技（集团）股份有限公司 公司于 2023 年 4 月 18 日、2023 年 5 月 12 日分别召开公司第五 届董事会第三十五次会议、第五届监事会第十九次会议、2022 年年度 股东大会，审议通过《关于公司预计为控股子公司提供担保额度的议 案》，同意公司自 2022 年年度股东大会通过之日起十二个月内对成电 医星提供不超过 5,000 万元的担保。实际办理中在额度范围内授权公 司管理层具体实施相关事宜，公司授权董事长签署担保/反担保等相 关文件。具体内容详见 2023 年 4 月 19 日、2023 年 5 月 13 日刊登于 《证券时报》及巨潮资讯网 (http://www.cninfo.com.cn) 的公告。 本次担保事项在公司第五届董事会第三十五次会议、第五届监事 会第十九次会议和 2022 年年度股东大会审议通过的担保额度范围内， 无须再次提交公司董事会、监事会或股东大会审议。 三、被担保人基本情况 继续提供担保的公告 1、名称：成都成电医星数字健康软件有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-003 上海延华智能科技（集团）股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、股票交易异常波动情况 上海延华智能科技（集团）股份有限公司（以下简称"公司"或 "上市公司"）（证券简称：延华智能，股票代码：002178）股票于 2024 年 1 月 4 日、2024 年 1 月 5 日连续两个交易日收盘价格涨幅偏 离值累计超过 20%，根据《深圳证券交易所交易规则》的有关规定， 属于股票交易异常波动。 二、公司关注并核实情况的说明 针对公司股票交易异常波动，公司对有关事项进行了核实，现就 有关情况说明如下： 1、截至本公告披露日，未发现公司前期所披露的信息存在需要 更正、补充之处。 2、截至本公告披露日，未发现近期公共传媒报道了可能或已经 对公司股票交易价格产生较大影响的未公开重大信息。 3、目前公司日常的经营情况正常、管理有序，内外部经营环境 未发生重大变化。 4、公司目前无控股股东、无实际控制人。经向公司第一大股东 华融（天津自贸试验区）投资有限公司（以 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-001 上海延华智能科技（集团）股份有限公司 关于收到《行政处罚决定书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、基本情况 上海延华智能科技（集团）股份有限公司（以下简称"公司"）于 2023 年 6 月 2 日收到中国证券监督管理委员会(以下简称"证监会") 下发的《中国证券监督管理委员会立案告知书》（编号：证监立案字 0032023021 号）。因涉嫌信息披露违法违规，根据《中华人民共和国 证券法》、《中华人民共和国行政处罚法》等法律法规，证监会决定对 公司立案。具体内容详见公司于 2023 年 6 月 3 日在《证券时报》、巨 潮资讯网(www.cninfo.com.cn)披露的《关于收到中国证券监督管理 委员会立案告知书的公告》（公告编号：2023-030）。 2023 年 12 月 5 日，公司及相关当事人收到中国证券监督管理委 员会上海监管局出具的《行政处罚事先告知书》（沪证监处罚字〔2023〕 29 号），具体内容详见公司于 2023 年 12 月 6 日在《证券时 ...

证券代码：002178 证券简称：延华智能 公告编号：2024-002 上海延华智能科技（集团）股份有限公司 关于公司相关诉讼进展情况暨 收到终结执行程序裁定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、诉讼背景：参股公司北京泰和康医疗生物技术有限公司业绩 承诺未达标，业绩补偿承诺人中汇乾鼎未履行相应补偿义务，故公司 起诉中汇乾鼎。 2、案件所处的诉讼阶段：法院裁定终结本次执行程序。 3、公司所处的当事人地位：申请执行人。 4、涉案的金额：股权转让款 184,500,000 元及按年化 12%利率 计算的资金占用费的总和，违约金等。 5、对上市公司损益产生的影响：暂无法准确判断法院终结本次 执行程序对公司本期利润或期后利润的影响。公司将遵循企业会计准 则及公司会计政策的相关规定，按照公司处理诉讼事项的一致性原则 进行会计处理，具体结果尚待确认。 一、本次诉讼事项受理的基本情况及进展 1、上海延华智能科技（集团）股份有限公司（以下简称"公司" 或"上市公司"）于 2022 年 8 月收到北京市第三中级人民法院通知， 公司作为原告与被告 ...